BlackRock Health Sciences Trust
BMEFinancial ServicesNASDAQAsset Management
Scan Results
Daily timeframeBlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC.
Market Cap
—
Beta
—
P/E (TTM)
5.68
P/E (Fwd)
—
EPS (TTM)
$8.06
EPS (Fwd)
—
ROE
19.3%
ROA
0.2%
Cash
$361
Total Debt
$688,351
Free CF
—
52W Change
23.1%
Annual Financials
Cash vs Debt
Where BME stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BME finished 13.00% above its 150-day moving average ($40.53) and 14.07% above its 200-day moving average ($40.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BME overbought or oversold?
At the September 3, 2026 close, BME's RSI(14) was 69.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, BME has $361 in cash with $688K in obligations. The ability to service this debt comfortably depends on continued operational cash generation. ROE of 19.3% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 0.2% is on the lower side, which is common in asset-heavy industries. Revenue has grown from -$26.0M (2022) to $77.5M (2025), reflecting a 399% increase over the period.
BlackRock Health Sciences Trust carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence BlackRock Health Sciences Trust's trajectory.